Clinical implications of a validated scoring system for disseminated intravascular coagulation

Critical Care Medicine

Volumn 32, Issue 12, 2004, Pages 2548-2549

  Heslet, Lars ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Disseminated intravascular coagulation score; Endothelial dysfunction; Preemptive criteria; Validation

Indexed keywords

ACTIVATED PROTEIN C; D DIMER; DROTRECOGIN; RECOMBINANT PROTEIN;

CLINICAL PRACTICE; DISSEMINATED INTRAVASCULAR CLOTTING; EDITORIAL; HEMOSTASIS; HUMAN; MORTALITY; PRIORITY JOURNAL; PROTHROMBIN TIME; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEPSIS; THROMBOCYTE COUNT; VALIDATION PROCESS;

BLOOD COAGULATION TESTS; CRITICAL CARE; CRITICAL ILLNESS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; GUIDELINES; HUMANS; INTENSIVE CARE UNITS; MALE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 10644283857     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000148088.91570.07     Document Type: Editorial

References (11)

1. Levi M, ten Cate H, van der Poll T: Disseminated intravascular coagulation: State of the art. Thromb Haemost 1999; 82:695-705
2. Wada H, Wakita Y, Nakase T, et al: Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Thromb Haemost 1995; 74:848-852
3. Taylor FB Jr, Toh CH, Hoots K, et al: Towards a definition, clinical and laboratory criteria and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86:1027-1030
4. Bakhtiari K, Meijers JCM, de Jonge E, et al: Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004; 32:2416-2421
5. Kinasewitz GT, Yan SB, Basson B, et al: PROWESS Sepsis Study Group. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis regardless of causative micro-organism. Crit Care 2004; 8:82-90
6. Levi M, de Jonge E, van der Poll T: New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med 2004; 36:41-49
7. Bernard GR, Vincent JL, Laterre PF, et al: Recombinant human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
8. Espana F, Vicente V, Tabernero D, et al: Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb Res 1990; 59:593-608
9. Strandberg K, Astermark J, Bjorgell O, et al: Complexes between activated protein C and protein C inhibitor measured with a new method: Comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis. Thromb Haemost 2001; 86:1400-1408
10. Laterre PF, Heiselman D: Management of patients with severe sepsis, treated by drotrecogin alfa (activated). Am J Surg 2002; 184(6A Suppl):S39-S46
11. Dempfle CE: Coagulopathy of sepsis. Thromb Haemost 2004; 91:213-224